I believe earnings are forecast to increase. There is robust demand and robust earnings growth. Doing a quick search it shows that some believe the stock can double in the coming months. IN the last few months the price has come down from $182 to $100 (ATH = $7,700+) Exclaimer: I hold these stocks and am buying more considering the recent earnings release on November 18, 2025.
Actors suggesting NUTX is undervalued
- Intrinsic value: Some analyses show the stock is deeply undervalued based on its intrinsic value compared to its current market price, with one source estimating it to be undervalued by over 100%.
- Analyst ratings: Investing.com reports a "Strong Buy" consensus based on multiple analysts, with an average 12-month price target suggesting a significant potential upside.
- Valuation multiples: The stock trades at a low Enterprise Value to EBITDA (EV/EBITDA) multiple of 2.1x and has a high free cash flow yield, indicating the market may not be fully appreciating its profitability.
- Management confidence: The company has a stock repurchase program, and management has stated that they believe the shares are undervalued, demonstrating their confidence in the company's prospects.
- Insider ownership: Management's significant insider ownership and consistent share purchases further signal long-term confidence in the business model.
Potential risks and concerns
- Legal and regulatory issues: Nutex's aggressive billing strategy has led to arbitration processes and potential legal risks.
- Governance and operations: The company has previously struggled with delivering financial reports on time, which can point to weaknesses in governance and operations.
Have other thoughts on Nutex Health?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
The user mstock holds no position in NasdaqCM:NUTX. Simply Wall St has no position in any of the companies mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The author of this narrative is not affiliated with, nor authorised by Simply Wall St as a sub-authorised representative. This narrative is general in nature and explores scenarios and estimates created by the author. The narrative does not reflect the opinions of Simply Wall St, and the views expressed are the opinion of the author alone, acting on their own behalf. These scenarios are not indicative of the company's future performance and are exploratory in the ideas they cover. The fair value estimates are estimations only, and does not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that the author's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
